* known systemic hypersensitivity to any of the vaccine components, or history of a life-threatening reaction to a vaccine containing any of the same substances. * dementia or any other cognitive condition at a stage that could interfere with following the study procedures based on investigator?s judgment. * self-reported thrombocytopenia, contraindicating intramuscular (im) vaccination based on investigator?s judgment * bleeding disorder, or receipt of anticoagulants in the past 21 days preceding inclusion, contraindicating im vaccination based on investigator?s judgment. * unstable acute or chronic illness that in the opinion of the investigator or designee poses additional risk as a result of participation or that could interfere with the study procedures. * moderate or severe acute illness/infection (according to investigator judgment) on the day of vaccination or febrile illness (temperature ? 38.0 c \[? 100.4 f\]). a prospective participant should not be included in the study until the condition has resolved or the febrile event has subsided. * receipt of any vaccine in the 30 days preceding or on the day of the first study vaccination or planned receipt of any vaccine between the first study vaccination and in the 30 days following the second study vaccination except for influenza vaccination, which may be received at any time in relation to study intervention. * prior administration of a coronavirus vaccine (sars-cov-2, sars-cov, middle east respiratory syndrome). * receipt of solid-organ or bone marrow transplants in the past 180 days. * receipt of anti-cancer chemotherapy in the last 90 days. * deprived of freedom by an administrative or court order, or in an emergency setting, or hospitalized involuntarily. * identified as an investigator or employee of the investigator or study center with direct involvement in the proposed study, or identified as an immediate family member (ie, parent, spouse, natural or adopted child) of the investigator or employee with direct involvement in the proposed study. * participation at the time of study enrollment (or in the 30 days preceding the first study vaccination) or planned participation during the present study period in another clinical study investigating a vaccine, drug, medical device, or medical procedure.

* known systemic hypersensitivity to any of the vaccine components, or history of a life-threatening reaction to a vaccine containing any of the same substances. * dementia or any other cognitive condition at a stage that could interfere with following the study procedures based on investigator?s judgment. * self-reported thrombocytopenia, contraindicating intramuscular (im) vaccination based on investigator?s judgment * bleeding disorder, or receipt of anticoagulants in the past 21 days preceding inclusion, contraindicating im vaccination based on investigator?s judgment. * unstable acute or chronic illness that in the opinion of the investigator or designee poses additional risk as a result of participation or that could interfere with the study procedures. * moderate or severe acute illness/infection (according to investigator judgment) on the day of vaccination or febrile illness (temperature ? 38.0 c \[? 100.4 f\]). a prospective participant should not be included in the study until the condition has resolved or the febrile event has subsided. * receipt of any vaccine in the 30 days preceding or on the day of the first study vaccination or planned receipt of any vaccine between the first study vaccination and in the 30 days following the second study vaccination except for influenza vaccination, which may be received at any time in relation to study intervention. * prior administration of a coronavirus vaccine (sars-cov-2, sars-cov, middle east respiratory syndrome). * receipt of solid-organ or bone marrow transplants in the past 180 days. * receipt of anti-cancer chemotherapy in the last 90 days. * deprived of freedom by an administrative or court order, or in an emergency setting, or hospitalized involuntarily. * identified as an investigator or employee of the investigator or study center with direct involvement in the proposed study, or identified as an immediate family member (ie, parent, spouse, natural or adopted child) of the investigator or employee with direct involvement in the proposed study. * participation at the time of study enrollment (or in the 30 days preceding the first study vaccination) or planned participation during the present study period in another clinical study investigating a vaccine, drug, medical device, or medical procedure.

known systemic hypersensitivity to any of the vaccine components, or history of a life-threatening reaction to a vaccine containing any of the same substances. dementia or any other cognitive condition at a stage that could interfere with following the study procedures based on investigator?s judgment. self-reported thrombocytopenia, contraindicating intramuscular (im) vaccination based on investigator?s judgment bleeding disorder, or receipt of anticoagulants in the past 21 days preceding inclusion, contraindicating im vaccination based on investigator?s judgment. unstable acute or chronic illness that in the opinion of the investigator or designee poses additional risk as a result of participation or that could interfere with the study procedures. moderate or severe acute illness/infection (according to investigator judgment) on the day of vaccination or febrile illness (temperature ? 38.0 c [? 100.4 f]). a prospective participant should not be included in the study until the condition has resolved or the febrile event has subsided. receipt of any vaccine in the 30 days preceding or on the day of the first study vaccination or planned receipt of any vaccine between the first study vaccination and in the 30 days following the second study vaccination except for influenza vaccination, which may be received at any time in relation to study intervention. prior administration of a coronavirus vaccine (sars-cov-2, sars-cov, middle east respiratory syndrome). receipt of solid-organ or bone marrow transplants in the past 180 days. receipt of anti-cancer chemotherapy in the last 90 days. deprived of freedom by an administrative or court order, or in an emergency setting, or hospitalized involuntarily. identified as an investigator or employee of the investigator or study center with direct involvement in the proposed study, or identified as an immediate family member (ie, parent, spouse, natural or adopted child) of the investigator or employee with direct involvement in the proposed study. participation at the time of study enrollment (or in the 30 days preceding the first study vaccination) or planned participation during the present study period in another clinical study investigating a vaccine, drug, medical device, or medical procedure.

known systemic hypersensitivity to any of the vaccine components, or history of a life-threatening reaction to a vaccine containing any of the same substances. dementia or any other cognitive condition at a stage that could interfere with following the study procedures based on investigator?s judgment. self-reported thrombocytopenia, contraindicating intramuscular (im) vaccination based on investigator?s judgment bleeding disorder, or receipt of anticoagulants in the past 21 days preceding inclusion, contraindicating im vaccination based on investigator?s judgment. unstable acute or chronic illness that in the opinion of the investigator or designee poses additional risk as a result of participation or that could interfere with the study procedures. moderate or severe acute illness/infection (according to investigator judgment) on the day of vaccination or febrile illness (temperature ? 38.0 c [? 100.4 f]). a prospective participant should not be included in the study until the condition has resolved or the febrile event has subsided. receipt of any vaccine in the 30 days preceding or on the day of the first study vaccination or planned receipt of any vaccine between the first study vaccination and in the 30 days following the second study vaccination except for influenza vaccination, which may be received at any time in relation to study intervention. prior administration of a coronavirus vaccine (sars-cov-2, sars-cov, middle east respiratory syndrome). receipt of solid-organ or bone marrow transplants in the past 180 days. receipt of anti-cancer chemotherapy in the last 90 days. deprived of freedom by an administrative or court order, or in an emergency setting, or hospitalized involuntarily. identified as an investigator or employee of the investigator or study center with direct involvement in the proposed study, or identified as an immediate family member (ie, parent, spouse, natural or adopted child) of the investigator or employee with direct involvement in the proposed study. participation at the time of study enrollment (or in the 30 days preceding the first study vaccination) or planned participation during the present study period in another clinical study investigating a vaccine, drug, medical device, or medical procedure.

participants are excluded from the study if any of the following criteria apply: - known systemic hypersensitivity to any of the vaccine components, or history of a life-threatening reaction to a vaccine containing any of the same substances. - dementia or any other cognitive condition at a stage that could interfere with following the study procedures based on investigator's judgment. - self-reported thrombocytopenia, contraindicating intramuscular (im) vaccination based on investigator's judgment - bleeding disorder, or receipt of anticoagulants in the past 21 days preceding inclusion, contraindicating im vaccination based on investigator's judgment. - unstable acute or chronic illness that in the opinion of the investigator or designee poses additional risk as a result of participation or that could interfere with the study procedures. - moderate or severe acute illness/infection (according to investigator judgment) on the day of vaccination or febrile illness (temperature ≥ 38.0°c [≥ 100.4°f]). a prospective participant should not be included in the study until the condition has resolved or the febrile event has subsided. - receipt of any vaccine in the 30 days preceding or on the day of the first study vaccination or planned receipt of any vaccine between the first study vaccination and in the 30 days following the second study vaccination except for influenza vaccination, which may be received at any time in relation to study intervention. - prior administration of a coronavirus vaccine (sars-cov-2, sars-cov, middle east respiratory syndrome). - receipt of solid-organ or bone marrow transplants in the past 180 days. - receipt of anti-cancer chemotherapy in the last 90 days. - participation at the time of study enrollment (or in the 30 days preceding the first study vaccination) or planned participation during the present study period in another clinical study investigating a vaccine, drug, medical device, or medical procedure.

participants are excluded from the study if any of the following criteria apply: - known systemic hypersensitivity to any of the vaccine components, or history of a life-threatening reaction to a vaccine containing any of the same substances. - dementia or any other cognitive condition at a stage that could interfere with following the study procedures based on investigator's judgment. - self-reported thrombocytopenia, contraindicating intramuscular (im) vaccination based on investigator's judgment - bleeding disorder, or receipt of anticoagulants in the past 21 days preceding inclusion, contraindicating im vaccination based on investigator's judgment. - unstable acute or chronic illness that in the opinion of the investigator or designee poses additional risk as a result of participation or that could interfere with the study procedures. - moderate or severe acute illness/infection (according to investigator judgment) on the day of vaccination or febrile illness (temperature ≥ 38.0°c [≥ 100.4°f]). a prospective participant should not be included in the study until the condition has resolved or the febrile event has subsided. - receipt of any vaccine in the 30 days preceding or on the day of the first study vaccination or planned receipt of any vaccine between the first study vaccination and in the 30 days following the second study vaccination except for influenza vaccination, which may be received at any time in relation to study intervention. - prior administration of a coronavirus vaccine (sars-cov-2, sars-cov, middle east respiratory syndrome). - receipt of solid-organ or bone marrow transplants in the past 180 days. - receipt of anti-cancer chemotherapy in the last 90 days. - participation at the time of study enrollment (or in the 30 days preceding the first study vaccination) or planned participation during the present study period in another clinical study investigating a vaccine, drug, medical device, or medical procedure.